Introduction

Monoclonal antibodies (mAbs) remain one of the most widely used therapeutic modalities across oncology, autoimmune diseases, and infectious diseases. In upstream development, accurate and timely measurement of mAb concentration is essential for clone selection, process optimisation, and early screening workflows. Conventional techniques such as enzyme-linked immunosorbent assays (ELISA) and conventional high-performance liquid chromatography (HPLC) offer reliable results but often require lengthy protocols, specialised instrumentation, and matrix clean-up. The Amperia™ platform offers a streamlined alternative, enabling consistent, sensor-based mAb quantification directly from cell culture supernatants using an inverse occupancy assay format, with adaptable throughput and simplified setup.

Assay format & workflow

Amperia™ uses an inverse occupancy format for mAb quantification. Each dip-style sensor is pre-coated with either Protein A or Protein G, which capture the Fc region of antibodies during the sample incubation step. Protein A binds strongly to human IgG subclasses, while Protein G provides broader species coverage, including mouse IgG1. The choice of sensor depends on the antibody source and assay requirements.

After incubation, a labelled detection molecule is added, which also binds to available Fc-binding sites on the sensor surface. As antibody concentration increases, more binding sites are occupied by the analyte, reducing availability for the detection molecule and resulting in a lower signal.

This inverse signal behaviour enables accurate quantification across a wide dynamic range, even in crude culture media.

Assays are run through the system’s touchscreen-guided workflow, using built-in protocol templates that support common run configurations. With intuitive setup and integrated analysis, Amperia enables streamlined and reproducible mAb quantification.

Assay Workflow Schematic.

• Sensor surface coated with Protein A or Protein G.

• Antibody (analyte) binds via Fc interaction.

• Detection molecule binds remaining unoccupied Fc-binding sites, generating an inverse signal.

Note:

Values shown are typical ranges based on internal testing. Actual throughput and hands-on time may vary depending on assay format, sample type, and workflow configuration. Detection range may vary depending on analyte affinity and assay conditions.

Data highlights

Amperia™ enables reliable antibody quantification using Protein A and Protein G, with performance across high, mid, and low ranges. The format supports a variety of species and subtypes, including human and mouse, ensuring consistent results across research and development.

Representative standard curves for Protein A and Protein G assays.

Where Amperia supports mAb workflows

Amperia™ supports a variety of mAb development workflows, particularly in early upstream settings where speed and scalability are key. With consistent performance in crude matrices and easy setup, it enables rapid iteration across multiple use cases.

Summary

Amperia™ provides a streamlined and scalable solution for mAb quantification – combining sensor-based detection, guided workflows, and broad matrix compatibility. It is well suited for early-stage process development, offering a practical alternative to traditional assays when speed, simplicity, and reproducibility matter most.

Relevant products

• Antibody Quantification Kit|Protein A: AK-Ab-001
• Protein A Sensor|Antibody Quantification (IgG): SN-001-10
• Antibody Quantification Kit|Protein G: AK-Ab-005
• Protein G Sensor|Antibody Quantification (IgG): SN-006-10